Cargando…
Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population‐based study
BACKGROUND: Patients with prostate cancer (PC) are at a high risk of developing secondary hematologic malignancies (SHMs) after radiation therapy (RT), while no study has assessed the relationship of different treatment modalities with the occurrence of SHMs after PC at early stage. This study aimed...
Autores principales: | Mo, Xiaofei, Zhou, Mingge, Yan, Hui, Chen, Xueqin, Wang, Yuetao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335824/ https://www.ncbi.nlm.nih.gov/pubmed/34189859 http://dx.doi.org/10.1002/cam4.4087 |
Ejemplares similares
-
Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy
por: Hultcrantz, Malin, et al.
Publicado: (2015) -
Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies
por: Pradelli, Danitza, et al.
Publicado: (2015) -
Hematologic malignancies in South Africa 2000–2006: analysis of data reported to the National Cancer Registry
por: Schonfeld, Sara J., et al.
Publicado: (2016) -
Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies
por: Ducros, Elodie, et al.
Publicado: (2012) -
Incidence and survival of hematological cancers among adults ages ≥75 years
por: Krok‐Schoen, Jessica L., et al.
Publicado: (2018)